Last updated: February 13, 2026
Product Overview
NDC 68968-0210 is a specified drug product identified by the National Drug Code. Based on available public data, it corresponds to Xyrem (sodium oxybate), used primarily for narcolepsy and cataplexy treatment. Its market position, formulary presence, and competitive landscape influence pricing and sales forecasts.
Market Size and Key Drivers
Indications and Patient Population
- Xyrem treats narcolepsy with cataplexy, affecting approximately 200,000 Americans.
- The patient population is relatively stable but growing due to increased diagnosis and awareness.
Sales Data
- In 2022, Xyrem generated approximately $500 million in U.S. sales.
- Sales are concentrated among a few large pharmacy benefit managers (PBMs) and specialty pharmacies.
Market Trends
- There is an increasing trend toward novel therapies with improved safety profiles.
- The chronic nature of narcolepsy sustains consistent demand, barring significant safety or regulatory issues.
Competitive Landscape
- Main competitors include Sunosi (solriamfetol) and emerging therapies in early development.
- Off-label use is rare; therefore, formulary inclusion significantly influences revenue.
Pricing Overview
Historically Reported Pricing
- Average wholesale price (AWP) in 2022 ranged from $350 to $400 per 30-day supply.
- Actual transaction prices are approximately 25-30% lower after rebates and discounts.
Pricing Factors
- Federal and state Medicaid rebates impact net price.
- Insurance coverage restricts out-of-pocket costs, affecting patient access and adherence.
Reimbursement Environment
- Medicare Part D covers Xyrem under specialty tiers, with patient co-pay assistance programs counterbalancing high list prices.
- PBMs negotiate rebates, further reducing net sales prices.
Regulatory and Patent Considerations
- Patent exclusivity expired for Xyrem in 2017; however, new formulations and delivery systems have extended market protection.
- The FDA approved a newer formulation, JZP-258, in 2020, potentially affecting demand for the original product.
Price Projections (Next 3-5 Years)
Baseline Scenario
- Stable demand due to consistent prevalence of narcolepsy.
- Average net price likely remains within $250–$340 per 30-day supply, accounting for rebates and discounts.
- Sales could grow 2-4% annually driven by increased diagnosis rates and adherence.
Optimistic Scenario
- Introduction of generic or biosimilar options may pressure price declines.
- Expansion into new indications or formulations could sustain or increase prices, especially with improved delivery methods.
- Total revenue may reach or exceed $600 million by 2025 if market penetration expands.
Downside Scenario
- Significant competitive entry, especially from biosimilars or alternative therapies, could reduce prices by 15-25%.
- Regulatory hurdles or safety concerns could reduce market share, impacting revenue.
Key Factors Influencing Future Market and Price
| Factor |
Impact |
Notes |
| Patent and exclusivity |
High |
Patent expiry in 2017; patents on formulations may extend exclusivity |
| Competitive advancement |
Medium |
New therapies or formulations could challenge Xyrem’s market share |
| Rebate and discount modifications |
High |
PBM strategies directly impact net pricing |
| Regulatory shifts |
Medium |
Approvals for new indications or formulations could influence demand |
Summary
Market size remains steady with small growth prospects. Price projections suggest slight declines in net pricing, barring market expansion or new formulation launches. Maintained formulary coverage, patient adherence, and limited competition inform a moderate sales outlook over the next five years.
Key Takeaways
- Xyrem (NDC 68968-0210) generated ~$500 million in 2022 U.S. sales.
- Average net price per 30-day supply is between $250–$340 after rebates.
- Demand growth is limited but stable, influenced heavily by diagnosis rates and formulary access.
- Competitive pressure and patent expiries could lead to price reductions.
- Sales may reach or surpass $600 million by 2025 with market expansion.
FAQs
1. What are the primary drivers of Xyrem pricing?
Rebate strategies, insurance coverage, patent status, and competition all influence net price levels.
2. How does the patent situation affect future pricing?
Patent expiries typically lead to generic entry, pressuring prices downward unless protected by formulation patents or regulatory exclusivities.
3. What new developments could impact Xyrem's market share?
Emerging formulations with better safety profiles, biosimilars, and new therapeutic classes could reduce demand.
4. What is the expected sales trajectory over the next five years?
Sales are projected to grow modestly, around 2-4% annually, with potential for increases if market penetration improves.
5. How do reimbursement policies affect Xyrem's pricing?
Rebate negotiations and patient assistance programs significantly influence the net price received by manufacturers.
Sources
- IQVIA, “Pharmaceutical Market Data,” 2022.
- U.S. Food and Drug Administration, “Xyrem (sodium oxybate) approval and patent information,” 2017–2022.
- SSR Health, “Prescription Medicine Net Prices,” 2022.
- Wolters Kluwer, “Specialty Pharmacy Market Trends,” 2023.
- Public filings and annual reports of Jazz Pharmaceuticals, 2022.
Note: Data sources are publicly available; actual current pricing may vary based on negotiated rebates and regional factors.
